With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...

What you’ll pay for Entyvio depends on your insurance coverage, your treatment plan, and potential coupons and savings programs. For example, Entyvio’s cost with Medicare varies based on your specific ...

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Deerfield, Ill., May 20, 2014, and Osaka, Japan, May ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...

More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerative colitis. The new ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

"These data from the VICTORY Consortium highlight the effectiveness of Entyvio in achieving mucosal healing and clinical remission in the real-world, and support the use of Entyvio as a first-line ...

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...